A., Brenner, C
Interactions with receptors such as LDLR and LDL receptor-related protein 1 (LRP1) are pivotal for APOE-mediated lipid and A metabolism
Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data
2,339 participants were randomised to retatrutide 4mg, 9mg or 12mg weekly (titrated from 2mg in four-weekly steps) or placebo
Tirzepatide: A Comparative Look When comparing Retatrutide vs tirzepatide, also developed by Eli Lilly, key differences include Retatrutide's unique ability to activate three receptors: GLP-1, GIP, and GCG, versus tirzepatide's two